PLOS ONE: Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models
Affiliations Drug Discovery/Cancer Drug Mechanisms Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia, School of Medicine, University of Queensland, Brisbane, Queensland, Australia, Department of Otolaryngology, Head and Neck Surgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia

About the Authors

Glen M. Boyle Contributed equally to this work with: Glen M. Boyle, Marjorie M. A. D'Souza * E-mail: Glen.Boyle@qimrberghofer.edu.au Affiliation Drug Discovery/Cancer Drug Mechanisms Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia Marjorie M. A. D'Souza Contributed equally to this work with: Glen M. Boyle, Marjorie M. A. D'Souza Affiliations Drug Discovery/Cancer Drug Mechanisms Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia, School of Medicine, University of Queensland, Brisbane, Queensland, Australia Carly J. Pierce Affiliation Drug Discovery/Cancer Drug Mechanisms Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia Ryan A. Adams Affiliations Drug Discovery/Cancer Drug Mechanisms Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia, School of Medicine, University of Queensland, Brisbane, Queensland, Australia, Department of Otolaryngology, Head and Neck Surgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia Aaron S. Cantor Affiliation Drug Discovery/Cancer Drug Mechanisms Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia Jenny P. Johns Affiliation Drug Discovery/Cancer Drug Mechanisms Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia Lidia Maslovskaya Affiliation Drug Discovery/Cancer Drug Mechanisms Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia Victoria A. Gordon Affiliation QBiotics Ltd., Yungaburra, Queensland, Australia Paul W. Reddell Affiliation QBiotics Ltd., Yungaburra, Queensland, Australia Peter G. Parsons Affiliation Drug Discovery/Cancer Drug Mechanisms Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia

Competing Interests

The authors of this manuscript have the following competing interests: GMB was a previous recipient of a fellowship co-sponsored by QBiotics and the Queensland State Government. PGP has received consulting payments and contract research funding from QBiotics Ltd. VAG and PWR have ownership interests (including patents) in QBiotics Ltd. and the compound. No potential conflicts of interest were disclosed by the other authors. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: GMB VAG PWR PGP. Performed the experiments: GMB MMAD CJP RAA ASC JPJ LM PGP. Analyzed the data: GMB MMAD CJP RAA ASC JPJ LM PGP. Contributed reagents/materials/analysis tools: GMB MMAD CJP RAA ASC JPJ LM VAG PWR PGP. Wrote the paper: GMB VAG PWR PGP.